Schizophrenia News and Research

Latest Schizophrenia News and Research

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work?

26 Apr 2013

New technologies speed health care delivery, reduce costs, pioneer new therapies

The current special issue of Technology and Innovation - Proceedings of the National Academy of Inventors, devoted to studies on medical technology and health care delivery, focuses on a wide range of topics, from new technologies to reduce the cost of health care to understanding the human microbiome.

25 Apr 2013

Schizophrenia patients misinterpret anger

A study shows that patients with schizophrenia struggle to recognize angry facial expressions, often mistaking them for fear.

25 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than people without schizophrenia.

25 Apr 2013

Research supports polygenic phenotype in schizophrenia

Cumulative genetic risk for schizophrenia has been linked to impaired prefrontal brain activity, in findings that support an additive genetic risk model for a polygenic phenotype.

25 Apr 2013

Scientists to develop technology for unprecedented new understanding of how the brain works

The newly proposed scientific project to understand the most complicated 3 pounds of material in the world - the human brain - is the topic of an article in the current edition of Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

25 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Advanced microscope reveals process where mutations lead to autism and other diseases

Using spinning disk microscopy on barely day-old zebra fish embryos, University of Oregon scientists have gained a new window on how synapse-building components move to worksites in the central nervous system.

22 Apr 2013

Study: Stem cell transplant heals neurological deficits in mice

For the first time, human embryonic stem cells have been transformed into nerve cells that helped mice regain the ability to learn and remember.

22 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Excess glutamate drives schizophrenia in high-risk individuals

An excess of the brain neurotransmitter glutamate may cause a transition to psychosis in people who are at risk for schizophrenia, reports a study from investigators at Columbia University Medical Center published in the current issue of Neuron.

19 Apr 2013

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.

18 Apr 2013

New research reveals how acute stress primes brain for improved performance

Overworked and stressed out? Look on the bright side. Some stress is good for you. "You always think about stress as a really bad thing, but it's not," said Daniela Kaufer, associate professor of integrative biology at the University of California, Berkeley.

17 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

Electroconvulsive therapy improves quality of life in patients with severe depression

Patients whose severe depression goes into remission for six months following electroconvulsive therapy report a quality of life similar to that of healthy individuals, researchers say.

16 Apr 2013

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

Johns Hopkins researchers to highlight progress in genetic research at international meeting

Johns Hopkins genetics researchers Aravinda Chakravarti, Ph.D., and David Valle, M.D., will each present at the joint conference of the Human Genome Meeting 2013 and the 21st International Congress of Genetics.

15 Apr 2013

Nearly 8% of patients in VHA visit emergency department two or more times per year: Study

Even with health insurance, ready access to preventive, specialty and behavioral health care and comprehensive electronic medical records, nearly 8 percent of patients in the Veterans Health Administration visit the emergency department two or more times per year, according to a study published online Tuesday in Annals of Emergency Medicine ("What Drives Frequent Emergency Department Use in an Integrated Health System: National Data from the Veterans Health Administration").

15 Apr 2013

Stigma of mental illness, a public health concern

An international study found that despite widespread acceptance that mental illness is a disease that can be effectively treated, a common "backbone" of prejudice exists that unfairly paints people with conditions such as depression and schizophrenia as undesirable for close personal relationships and positions of authority.

12 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

New technologies speed health care delivery, reduce costs, pioneer new therapies

Schizophrenia patients misinterpret anger

Schizophrenia cardiovascular risk under-recognized in primary care

Research supports polygenic phenotype in schizophrenia

Scientists to develop technology for unprecedented new understanding of how the brain works

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Advanced microscope reveals process where mutations lead to autism and other diseases

Study: Stem cell transplant heals neurological deficits in mice

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Excess glutamate drives schizophrenia in high-risk individuals

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

New research reveals how acute stress primes brain for improved performance

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Electroconvulsive therapy improves quality of life in patients with severe depression

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

Johns Hopkins researchers to highlight progress in genetic research at international meeting

Nearly 8% of patients in VHA visit emergency department two or more times per year: Study

Stigma of mental illness, a public health concern

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Schizophrenia News and Research

Latest Schizophrenia News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in